Hiroto Hatano
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hiroto Hatano has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
Hiroshi Nokihara
2 shared publications- Tatsuya Yoshida
Department of Thoracic Oncology, National Cancer Center Hospital , 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045
2 shared publications Yuji Uehara
2 shared publications- Yuji Uehara
Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan
2 shared publications Akane Ishida
Natl Ctr Global Hlth & Med, Dept Resp Med, 1-21-1 Toyama,Shinjuku Ku, Tokyo 1628655, Japan
1 shared publicationAyu Kiritani
1 shared publication
Latest Publications
- 31 August 2026
- Published by Elsevier in Lung Cancer
- Vol. 220
Clinical outcomes and genomic features of uncommon EGFR exon 19 deletion subtypes in osimertinib-treated non-small cell lung cancer
- 31 August 2026
- Published by Elsevier in Lung Cancer
- Vol. 220
Clinical outcomes and genomic features of uncommon EGFR exon 19 deletion subtypes in osimertinib-treated non-small cell lung cancer
- Open Access
Targeting Classical EGFR Mutations in Lung Cancer: Twenty Years of Progress and Beyond
The discovery of activating epidermal growth factor receptor (EGFR) mutations transformed the management of non-small cell lung cancer and has driven two decades of therapeutic advances in precision oncology across metastatic, resectable, and unresectable locally advanced disease, including central nervous system (CNS) control. Consequently, treatment outcomes for patients with tumors harboring classical EGFR mutations have markedly improved. Despite these advances, many questions remain unanswered, and the expanding number of treatment options has created new challenges in treatment selection and sequencing. This narrative review summarizes contemporary data on the management of classical EGFR-mutant NSCLC, encompassing novel therapeutic approaches across disease stages, biomarker-informed resistance strategies, multimodality treatment integrating radiotherapy, CNS-directed management, and challenging scenarios such as small-cell transformation. We also discuss emerging fourth-generation inhibitors, nucleic-acid delivery platforms, and data-enabled personalized treatment. We highlight evolving standards of care, unresolved knowledge gaps, and research priorities for the next decade.
Open AccessTargeting Classical EGFR Mutations in Lung Cancer: Twenty Years of Progress and Beyond
The discovery of activating epidermal growth factor receptor (EGFR) mutations transformed the management of non-small cell lung cancer and has driven two decades of therapeutic advances in precision oncology across metastatic, resectable, and unresectable locally advanced disease, including central nervous system (CNS) control. Consequently, treatment outcomes for patients with tumors harboring classical EGFR mutations have markedly improved. Despite these advances, many questions remain unanswered, and the expanding number of treatment options has created new challenges in treatment selection and sequencing. This narrative review summarizes contemporary data on the management of classical EGFR-mutant NSCLC, encompassing novel therapeutic approaches across disease stages, biomarker-informed resistance strategies, multimodality treatment integrating radiotherapy, CNS-directed management, and challenging scenarios such as small-cell transformation. We also discuss emerging fourth-generation inhibitors, nucleic-acid delivery platforms, and data-enabled personalized treatment. We highlight evolving standards of care, unresolved knowledge gaps, and research priorities for the next decade.
- 25 June 2026
- Published by Elsevier in Lung Cancer
- Vol. 218, 109504
A new surface to target: Glypican-1-directed ADCs in lung squamous cell carcinoma
- 25 June 2026
- Published by Elsevier in Lung Cancer
- Vol. 218, 109504
A new surface to target: Glypican-1-directed ADCs in lung squamous cell carcinoma
- Open Access
- 27 December 2024
- Published by Wiley in Thoracic Cancer
- Vol. 16 (3)
EGFR, TP53, and CUL3 Triple Mutation in Non‐Small Cell Lung Cancer and its Potentially Poor Prognosis: A Case Report and Database Analysis
Concurrent mutations in tumor protein p53 (TP53) or Kelch‐like ECH‐associated protein 1‐nuclear factor erythroid 2‐related factor 2‐pathway components are linked to poor outcomes in epidermal growth factor receptor (EGFR)‐mutant non‐small cell lung cancer (NSCLC), but the impact of triple mutations remains unclear. We report a case of EGFR‐, TP53‐, and Cullin 3 (CUL3)‐mutant NSCLC in a 43‐year‐old woman with widespread metastases at diagnosis, including those in the contralateral lung, distant lymph nodes, pericardium, liver, bones, left adrenal gland, and brain. She received osimertinib as first‐line therapy, but pericardial effusion and liver metastases progressed rapidly over 3 months, and she was switched to carboplatin and pemetrexed. By the eighth cycle of pemetrexed, the bone metastases had progressed, resulting in disseminated intravascular coagulation (DIC) due to bone marrow carcinomatosis. The patient received third‐line therapy with albumin‐bound paclitaxel and fourth‐line therapy with docetaxel, but further treatment was suspended owing to DIC progression. She passed away 23 months after the initiation of osimertinib. Public database analysis revealed that the EGFR/TP53/CUL3 triple mutation accounts for 0.4% of EGFR‐mutant NSCLC cases, yielding significantly shorter survival than EGFR mutations alone and likely shorter than EGFR/TP53 double mutations. Gaining a deeper understanding of the clinical significance of coexisting genetic mutations in patients with EGFR‐mutant NSCLC will be crucial to develop future therapies.
- 27 December 2024
- Published by Wiley in Thoracic Cancer
- Vol. 16 (3)
Open AccessEGFR, TP53, and CUL3 Triple Mutation in Non‐Small Cell Lung Cancer and its Potentially Poor Prognosis: A Case Report and Database Analysis
Concurrent mutations in tumor protein p53 (TP53) or Kelch‐like ECH‐associated protein 1‐nuclear factor erythroid 2‐related factor 2‐pathway components are linked to poor outcomes in epidermal growth factor receptor (EGFR)‐mutant non‐small cell lung cancer (NSCLC), but the impact of triple mutations remains unclear. We report a case of EGFR‐, TP53‐, and Cullin 3 (CUL3)‐mutant NSCLC in a 43‐year‐old woman with widespread metastases at diagnosis, including those in the contralateral lung, distant lymph nodes, pericardium, liver, bones, left adrenal gland, and brain. She received osimertinib as first‐line therapy, but pericardial effusion and liver metastases progressed rapidly over 3 months, and she was switched to carboplatin and pemetrexed. By the eighth cycle of pemetrexed, the bone metastases had progressed, resulting in disseminated intravascular coagulation (DIC) due to bone marrow carcinomatosis. The patient received third‐line therapy with albumin‐bound paclitaxel and fourth‐line therapy with docetaxel, but further treatment was suspended owing to DIC progression. She passed away 23 months after the initiation of osimertinib. Public database analysis revealed that the EGFR/TP53/CUL3 triple mutation accounts for 0.4% of EGFR‐mutant NSCLC cases, yielding significantly shorter survival than EGFR mutations alone and likely shorter than EGFR/TP53 double mutations. Gaining a deeper understanding of the clinical significance of coexisting genetic mutations in patients with EGFR‐mutant NSCLC will be crucial to develop future therapies.
- 9 November 2024
- Published by Elsevier in Respiratory Investigation
- Vol. 62 (6) , 1227-1232
Preliminary investigation of the significance of cavitary lesions in recurrent hemoptysis following bronchial artery embolization for nontuberculous mycobacterial pulmonary disease
- 9 November 2024
- Published by Elsevier in Respiratory Investigation
- Vol. 62 (6) , 1227-1232
Preliminary investigation of the significance of cavitary lesions in recurrent hemoptysis following bronchial artery embolization for nontuberculous mycobacterial pulmonary disease